A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors
This is a phase II study to investigate the effect of treprolizumab on tumor control and survival in high-risk renal cancer after radical nephrectomy. Patients will be treated with treprolizumab, which will be administered every 3 weeks until tumor recurrence or intolerable toxicities
High-risk Renal Cell Carcinoma
DRUG: Tremelimumab
PFS, Duration from patient enrollment to disease progression, assessed up to 3 years|OS, Duration from the start of randomization until death due to any cause, assessed up to 3 years
This is a phase II study to investigate the effect of treprolizumab on tumor control and survival in high-risk renal cancer after radical nephrectomy. Patients will be treated with treprolizumab, which will be administered every 3 weeks until tumor recurrence or intolerable toxicities. The primary outcome measure was PFS and OS.